Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 655 with mFOLFOX6 and Bevacizumab in Metastatic Colorectal Cancer
NCT00625651Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2007
- Primary completion
- Aug 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of conatumumab in metastatic colorectal cancer (mCRC) (3 arms), sponsored by Amgen. Primary endpoint: Progression-Free Survival. Started Oct 2007; status: completed.
02
Drugs
conatumumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00625651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625651.